Arcturus Therapeutics announced that Mark R. Herbert, vice president of Business Development and Alliance Management, has been appointed to serve as interim president, effective immediately.
This news follows the decision of the Arcturus Board of Directors to terminate Joseph E. Payne as president and chief executive officer.
“Mark is a seasoned biotechnology leader who has gained a deep understanding of our strategy, business and partnerships since joining the company in 2015,” said Stuart Collinson Ph.D., Executive Chairman of the Arcturus Board of Directors. “We are confident that Mark, working with me, the board and the management team, will help us to achieve our objective of developing innovative RNA medicines with the potential to transform the lives of patients with serious diseases.”
Before joining Arcturus, Herbert most recently was Head of U.S. Business Development and Sales at STA Pharmaceutical Co.